Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status-Reference-Cited by-同舟云学术

Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status

Published:2019-12-27 Issue:4 Volume:9 Page:1383-1391
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Adachi Yuichi¹^ORCID,Tamiya Akihiro¹^ORCID,Taniguchi Yoshihiko¹,Enomoto Takatoshi¹,Azuma Kouji¹,Kouno Shunichi¹,Inagaki Yuji¹,Saijo Nobuhiko¹,Okishio Kyoichi²,Atagi Shinji²

Affiliation:

1. Department of Internal Medicine National Hospital Organization Kinki‐Chuo Chest Medical Center Sakai Japan

2. Clinical Research Center National Hospital Organization Kinki‐Chuo Chest Medical Center Sakai Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2807

Reference27 articles.

1. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

3. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

4. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study

5. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of PD-1 inhibitors plus chemotherapy with or without endostatin for stage IV lung squamous cancer: a retrospective study;Frontiers in Immunology;2024-06-07

2. Site-Specific Response and Resistance Patterns in Patients with Advanced Non-Small-Cell Lung Cancer Treated with First-Line Systemic Therapy;Cancers;2024-06-04

3. Organ‐specific responses to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicentre, retrospective study;Liver International;2024-04-15

4. Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer;BMC Cancer;2024-04-08